ESMO 2025

An abstract describing the study design for Isofol’s ongoing clinical phase Ib/II study with arfolitixorin has been accepted for presentation at the annual cancer congress ESMO 2025 in Berlin, Germany between October 17-21.

Information about the abstract

Title: ”Phase Ib/II study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC)”

Speaker: Sebastian Stintzing

Authors: Sebastian Stintzing, Arndt Stahler, Isabel Löwstedt, Marcus Thuresson, Roger Tell

Abstract number: TPS254

The abstract was published online on ASCO GI’s website and is also be available below: